Unlocking the full clinical utility of mRNA liquid biopsy.
Moving beyond simple mutation detection to a dynamic readout of tumor activity — enabling earlier, more precise diagnosis and risk stratification, and identifying sooner who may benefit from imaging, biopsy or therapy.
Monitoring at every stage of the journey.
Our liquid biopsy supports ongoing, minimally invasive monitoring for every patient.
Post-surgical status & MRD
After resection, sensitive detection of minimal residual disease gives early molecular insight into whether microscopic disease remains — supporting decisions on adjuvant therapy and follow-up.
Recurrence detection
During routine surveillance or as symptoms evolve, mRNA levels can signal recurrence earlier than imaging or conventional biomarkers.
Therapy response monitoring
Repeat testing during treatment reveals real-time changes in tumor biology — is the current approach working, or does it need to change?
Why choose our diagnostics?
Non-invasive
Unlike tissue biopsy, our diagnostics are based on a small amount of blood or saliva.
Highly accurate
Peer-reviewed research supports mRNA for accurate testing — enabling early detection and a correct diagnosis.
Tried and true
Backed by over 60 scientific studies and used by leading doctors and over 10,000 patients.
Providers, order your test here
Order NETest 2.0® or PROSTest® through our portal or with the requisition form — kits ship directly to your office.